MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing), By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others), By End-use

Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing), By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others), By End-use

Forecast Period2025-2029
Market Size (2023)USD 22.76 billion
CAGR (2024-2029)6.58%
Fastest Growing SegmentSequencing by Synthesis
Largest MarketNorth America

MIR Consumer Healthcare

Market Size (2029)

USD 33.23 billion

Market Overview

Global MiRNA Sequencing and Assay Market was valued at USD 22.76 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 6.58% through 2029.

The Global MiRNA Sequencing and Assay Market is at the forefront of genomics and molecular biology, representing a dynamic and rapidly evolving sector. MicroRNAs (miRNAs) are small RNA molecules that play a pivotal role in regulating gene expression across various biological processes. This market has experienced substantial growth in recent years, fueled by the increasing recognition of miRNAs' significance in understanding disease mechanisms and identifying potential therapeutic targets. With their involvement in crucial cellular pathways related to development, immunity, and disease, miRNAs have become key targets for research and diagnostic applications.

Technological advancements have played a pivotal role in driving market expansion by enhancing the efficiency and accessibility of miRNA profiling. Next-generation sequencing (NGS) and microarray-based techniques have revolutionized the field, enabling comprehensive miRNA analysis with unprecedented speed and accuracy. These platforms offer high-throughput capabilities, allowing researchers to analyze thousands of miRNAs simultaneously from a single sample. Furthermore, the integration of advanced bioinformatics tools has streamlined data analysis and interpretation, empowering researchers to extract meaningful insights from complex miRNA datasets.

The Global MiRNA Sequencing and Assay Market represents a vital component of the genomics and molecular biology landscape, driven by the growing recognition of miRNAs' role in health and disease. With increasing demand for personalized medicine, technological advancements, and a deeper understanding of miRNA biology, this market is poised for continued growth and innovation. As researchers and clinicians harness the power of miRNA sequencing and assay technologies to unlock new insights into disease mechanisms and develop targeted therapies, the potential for transformative advancements in healthcare is immense.


Key Market Drivers

Rising Prevalence of Chronic Diseases

The Global MiRNA Sequencing and Assay Market is witnessing a significant boost due to the rising prevalence of chronic diseases worldwide. Chronic diseases, which include conditions such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders, have become a global health concern, contributing to a substantial portion of morbidity and mortality. MiRNA sequencing and assay technologies are playing a pivotal role in addressing the challenges posed by these chronic diseases.

Researchers and clinicians are increasingly turning to miRNA profiling to unravel the intricate web of molecular events associated with chronic diseases. By identifying specific miRNA signatures or dysregulations, they can gain insights into disease mechanisms and develop innovative diagnostic and therapeutic strategies. MiRNA sequencing and assays provide the tools necessary to comprehensively analyze these small but influential RNA molecules.

Advancements in Sequencing Technologies

Advancements in sequencing technologies have played a pivotal role in propelling the Global MiRNA Sequencing and Assay Market to new heights. MiRNA sequencing and assay technologies have undergone remarkable improvements, leading to increased efficiency, accuracy, and affordability, which have in turn stimulated their adoption and utilization across various research and clinical applications.

In addition to NGS, microarray-based techniques have also advanced, further diversifying the tools found at for miRNA profiling. Microarrays provide a complementary approach to miRNA analysis, allowing researchers to simultaneously examine the expression levels of numerous miRNAs on a single chip. The development of highly sensitive and specific microarray platforms has extended the reach of miRNA sequencing and assays, offering options that cater to different research needs and budgets.


MIR Segment1

Microarray-Based Techniques

Microarray-based techniques have emerged as a significant driver behind the growth of the Global MiRNA Sequencing and Assay Market. These techniques have played a crucial role in expanding the range of found at tools for miRNA analysis, complementing the dominant next-generation sequencing (NGS) technologies. Microarrays offer unique advantages that contribute to their popularity in miRNA research and diagnostics, thereby boosting the market.

Microarray platforms have evolved significantly, offering improved sensitivity and specificity. These enhancements have increased the accuracy and reliability of miRNA data generated through microarray-based techniques, making them a viable option for various research and clinical applications. With the ability to detect subtle changes in miRNA expression, microarrays have become indispensable in identifying miRNA dysregulations associated with diseases.

Microarray-based techniques have also demonstrated their value in bridging the gap between research and clinical applications. Their ability to rapidly generate miRNA expression data has led to their integration into diagnostic and prognostic assays. By identifying miRNA signatures associated with various diseases, microarrays are paving the way for the development of non-invasive and early diagnostic tools. As the shift toward personalized medicine and precision diagnostics gains momentum, microarrays are becoming increasingly relevant in translating miRNA research findings into actionable insights for patient care.

Key Market Challenges

Data Analysis Complexities

Data analysis complexities represent a significant hindrance to the growth of the Global MiRNA Sequencing and Assay Market. MiRNA sequencing generates vast amounts of data, making it a powerful tool for researchers seeking insights into gene regulation and disease mechanisms. However, the intricate nature of miRNA data, coupled with the need for specialized bioinformatics expertise, poses a considerable challenge for the market.

The identification and quantification of miRNAs require the use of bioinformatics tools that are specifically designed for small RNA sequencing data. Researchers must employ algorithms that can accurately distinguish miRNAs from other small RNAs, such as tRNAs and rRNAs, while also dealing with issues like sequencing errors and variations in miRNA expression levels.

High Costs

The Global MiRNA Sequencing and Assay Market is a burgeoning sector in genomics and molecular biology, offering profound insights into gene regulation and its implications for various diseases. However, the market faces a substantial challenge in the form of high costs associated with miRNA sequencing and assay technologies. While these techniques hold immense promise, the financial burden they place on research laboratories, clinics, and diagnostic facilities can hinder their widespread adoption.

The reagents and consumables used in miRNA sequencing and assays contribute significantly to the overall cost. These specialized chemicals and kits are often more expensive than those used in conventional molecular biology techniques. The cost of reagents can become a major concern, particularly in high-throughput experiments that require large quantities of materials.


MIR Regional

Key Market Trends

Integration of Bioinformatics Tools

The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market. MiRNA sequencing and assays generate copious amounts of data, making it essential to harness sophisticated computational techniques for data analysis and interpretation. Bioinformatics tools have filled this crucial role, enhancing the efficiency and accessibility of miRNA research and applications.

Bioinformatics tools play a pivotal role in identifying differentially expressed miRNAs. These tools apply statistical methods to discern significant changes in miRNA expression levels between experimental conditions, such as healthy and disease states. This capability is critical for biomarker discovery and understanding the regulatory roles of miRNAs in various biological processes.

Rising Interest in Personalized Medicine

The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market. Personalized medicine represents a revolutionary approach to healthcare that tailors medical treatments and interventions to an individual's unique genetic and molecular profile. MiRNA sequencing and assays have become pivotal tools in the realization of this vision, driving increased demand and adoption of these technologies.

The concept of personalized medicine is gaining traction across various medical specialties, from oncology to cardiology, and from neurology to rare genetic diseases. As this trend continues to grow, the demand for miRNA sequencing and assays is set to increase in tandem. These technologies are instrumental in deciphering the genetic intricacies that underlie disease pathogenesis and therapeutic responses.

Segmental Insights

Technology Insights

Based on the Technology,

Application Insights

Based on the Application, Cancer emerged as the dominant segment in the global market for Global MiRNA Sequencing and Assay Market in 2023

Regional Insights

North America emerged as the dominant region in the Global MiRNA Sequencing and Assay Market in 2023, holding the largest market share. The United States and Canada, in particular, have highly advanced healthcare systems with a strong emphasis on research and innovation. The integration of miRNA profiling into clinical practice, precision medicine initiatives, and the development of targeted therapies has significantly contributed to the adoption of miRNA sequencing and assays. North America hosts a significant portion of the global pharmaceutical and biotechnology industry. These companies play a pivotal role in drug discovery and development, where miRNA profiling is extensively used for target identification, companion diagnostics, and biomarker discovery. The close collaboration between academia and the industry further fuels the demand for miRNA technologies.

Recent Developments

  • In June 2022, PerkinElmer, Inc.introduced three research-focused sample preparation kitsthe PG-Seq Rapid Kitv2, NEXTFLEX Small RNA-Seq Kit v4, and NEXTFLEX Rapid XP V2 DNA-Seq Kit. Theseproduct launches, in conjunction with the growing research and developmentefforts in the sequencing sector, are expected to sustain market expansion.
  • In December 2021, InteRNA Technologiesdisclosed the Investigational New Drug (IND) clearance from the U.S. FDA forits Phase I clinical trial involving the primary miRNA candidate administeredto patients with advanced solid tumors. These developments are expected todrive the expansion of the service segment.

Key Market Players

  • ThermoFisher Scientific, Inc.
  • Illumina,Inc.
  • QIAGEN N.V.
  • PerkinElmer,Inc.
  • Abcam plc
  • New England Biolabs, Inc.
  • Takara Bio USA Inc.
  • LexogenGmbH
  • NorgenBiotek Corp.
  • Maravai LifeSciences Holdings, Inc.

 

By Technology


  By Application


  By Workflow


  By End-use


  By Region

  • Sequencing By Synthesis
  • Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
  • Nanopore Sequencing
  • Sanger Sequencing
  • Single Molecule Real-time (SMRT) Sequencing
  • Cancer
  • Polyglutamine Diseases
  • Autoimmune Disease
  • Schizophrenia
  • Others
  • Library Preparation
  • Sequencing
  • Data Analysis & Storage
  • Pharmaceutical & Biotechnology Industry
  • Research and Academic Institutes
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.